Table 3 Synthesised primary and secondary outcomes of mould-active vs fluconazole prophylaxis

From: Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials

Outcome

Trials (patients)

RR (95% CI) a

P- value

Proven or probable IFI

18 (4802)

0.71 (0.52, 0.98)

0.03

Invasive aspergillosis

15 (4503)

0.53 (0.37, 0.75)

0.0004

Adverse events requiring antifungal treatment discontinuation or modification

16 (4493)

1.95 (1.24, 3.07)

0.004

IFI-related mortality

15 (4272)

0.67 (0.47, 0.96)

0.03

Invasive aspergillosis-related mortality

9 (2614)

0.62 (0.23, 1.71)

0.36

Overall mortality

16 (4870)

1.00 (0.88, 1.13)

0.96

  1. Abbreviations: CI=confidence interval; IFI=invasive fungal infection; RR=risk ratio.
  2. RR<1 represents an advantage of mould-active coverage using a random-effects model.
Back to article page